Yen Yun 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Apr 2, 2025
Insider Transaction Report
Form 4
Yen Yun
Director
Transactions
- Award
Options to Purchase Common Stock
2025-03-31+8,777→ 8,777 totalExercise: $1.21From: 2025-03-31Exp: 2030-03-31→ Common (8,777 underlying)
Holdings
- 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 5,000
Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying) - 833
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying) - 4,545
Options to Purchase Common Stock
Exercise: $2.33From: 2025-01-20Exp: 2030-01-20→ Common (4,545 underlying) - 5,786
Options to Purchase Common Stock
Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (5,786 underlying) - 4,527
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,527 underlying) - 5,263(indirect: By Sino-American Cancer FDD)
Warrants to Purchase Common Stock
Exercise: $57.00From: 2020-11-30Exp: 2025-11-30→ Common (5,263 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying) - 3,333
Options to Purchase Common Stock
Exercise: $16.80From: 2018-08-04Exp: 2023-08-04→ Common (3,333 underlying)
Footnotes (1)
- [F1]Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 8,777 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.